Co-Diagnostics, Inc. (NASDAQ:CODX) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET
Company Participants
Andrew Benson – IR
Dwight Egan – CEO
Brian Brown – CFO
Conference Call Participants
Operator
Good day, and welcome to the Co-Diagnostics Fourth Quarter and Full Year 2024 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today’s presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note, that this event is being recorded.
I would now like to turn the conference over to Andrew Benson, Investor Relations. Please go ahead, sir.
Andrew Benson
Good afternoon, everyone, and thank you all for participating in today’s conference call. On the line today from Co-Diagnostics, we have Dwight Egan, Chief Executive Officer; and Brian Brown, Chief Financial Officer.
Earlier today, Co-Diagnostics released financial results from the fourth quarter and full year ended December 31, 2024. A copy of the press release is available on the company’s website. We will begin the call with management’s prepared remarks, and then open the call to analyst Q&A.
Before we begin, we would like to inform the listeners that certain statements made by Co-Diagnostics during this call that are not historical facts are forward-looking statements. This include statements concerning the company’s Co-Dx PCR testing platform, which requires regulatory approval and marketing authorization for diagnostic use, and is not currently for sale. In addition – to diagnostic test developments and timing for commencement of clinical evaluations, actual outcomes and results may differ materially from what is expressed or implied in any statement.
Important factors which could cause actual results to differ materially from those in these forward-looking statements are detailed in Co-Diagnostics filings with the SEC. Co-Diagnostics assumes no obligation and expressly disclaims any duty to update any forward-looking statements, to reflect events or